Chr. Hansen Holding A/S (CHYHY)
|Net Income (ttm)||245.09M|
|Ex-Dividend Date||Nov 24, 2022|
|Day's Range||17.82 - 17.97|
|52-Week Range||11.78 - 21.40|
|Price Target||18.95 (+5.69%)|
|Earnings Date||Jan 12, 2023|
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products ... [Read more]
In 2022, CHYHY's revenue was 1.22 billion, an increase of 13.05% compared to the previous year's 1.08 billion. Earnings were 225.10 million, a decrease of -73.37%.Financial numbers in EUR Financial Statements
According to 16 analysts, the average rating for CHYHY stock is "Hold." The 12-month stock price forecast is $18.95, which is an increase of 5.69% from the latest price.
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased...
NOVEMBER 23, 2022 – ANNOUNCEMENT NO. 11
Company announcement no. 6/2022 August 2, 2022
Company announcement no. 05/2022
Company announcement no. 03/2022
January 13, 2022
Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364
July 8, 2021
Company announcement No. 7
Continued strong organic growth momentum leads to upwards narrowing of full-year organic growth guidance
Company Announcement No. 01
Company Announcement No. 23/2020
Chr. Hansen Holding A/S enters into a definitive agreement to divest its Natural Colors business to EQT
Chr. Hansen Holding A/S has today entered into an agreement to divest its Natural Colors business to the EQT IX Fund for a cash consideration of 800 EUR million on cash and debt free basis. The transa...
Chr. Hansen Holding A/S acquires Jennewein Biotechnologie GmbH to enter and lead the high-growth Human Milk Oligosaccharides market
Chr. Hansen Holding A/S (“Chr. Hansen”) has today entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oli...
UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holding A/S
CHICAGO, July 28, 2020 /PRNewswire/ -- Lincoln International is pleased to announce that UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holdin...
Company Announcement No. 15/2020 - Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company s...